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 Type II diabetes is often associated with the presence of islet amyloid. Islet 
amyloid is aggregated fibrils composed primarily of the hormone peptide, islet amyloid 
polypeptide (IAPP), which is cosecreted with insulin from the secretory granules of the β-
cells in the islets of Langerhans of the pancreas. Despite the commonality of IAPP 
amyloid fibrils in the disease state, recent evidence suggests that the small oligomeric 
forms of IAPP consisting of a few monomers may be the cause of β-cell toxicity rather 
than fibrillar amyloid species. In this thesis we explore the relationship of small 
oligomeric forms of IAPP with their ability to bind and permeabilize the membranes of 
our model lipid system. We extend previous research by identifying the region of the 
peptide responsible for membrane binding, which is required for further membrane 
permeabilization. Insulin inhibits IAPP fibril formation and because of this inhibitory 
nature it has been suggested that it may also inhibit IAPP membrane binding and 
permeabilization. We show that insulin, which is co-secreted with IAPP from the 
secretory granules, does not inhibit the ability of IAPP to permeabilize membranes. 
Insulin in the act of inhibiting IAPP fibril formation maintains IAPP in a toxic small 
oligomeric form that more readily permeabilizes membranes than is observed with IAPP 
fibrils. Type II diabetes is an aging associated disease; one common change that occurs in 
the aging process is a decrease in membrane-localized cholesterol. Because of the 
stabilizing effect of cholesterol on the membrane we looked at the effect of IAPP 
permeabilization of large unilamellar vesicles (LUVs) with incorporated cholesterol and 
found that cholesterol dramatically reduces the ability of IAPP to permeabilize lipid 
membranes. In our dye leakage experiments, cholesterol plays a protective role against 
membrane permeabilization. In light of the complex environment of the secretory granule 
and the cell we conclude that insulin in its soluble form does not inhibit the ability of 
IAPP to permeabilize membranes, and cholesterol has a protective effect against 
permeabilization by IAPP. Other components of the secretory granule may have a 
cooperative effect in sequestering the toxic IAPP peptides and protecting the hormone 




Introduction to Islet Amyloid Polypeptide and Its Involvement in Type II Diabetes 
    
 
1.1 Islet Amyloid Is Present in the Disease State 
 Diabetes is a commonly used term that is applied to both Type I and Type II 
diabetes and although this work involves only Type II diabetes, the term diabetes will be 
used to refer specifically to this form of the disease. Type I and II diabetes occur from 
fundamentally different processes. Type I diabetes is an autoimmune disease that leads to 
a T-cell mediated immune system attack and destruction of the insulin secreting β-cells in 
the islets of Langerhans of the pancreas. The development of Type I diabetes occurs 
suddenly and almost invariably results in complete insulin dependence, requiring insulin 
monitoring and injections. Type II diabetes gradually develops and is characterized by 
defective insulin secretion, insulin resistance, a reduction in β-cell mass, increased β-cell 
apoptosis, and often the presence of islet amyloid. Several of these conditions alone do 
not constitute diabetes. Insulin resistance alone does not qualify as diabetes and is only 
one of the necessary steps that leads to diabetes. Insulin resistance is a precursor to the 
development of Type II diabetes and is often termed pre-diabetes. Insulin resistance leads 
to the development of Type II diabetes by requiring greater insulin, IAPP, and lipid 
synthesis from the β-cells, placing them under a constant state of stress (1). Unlike Type I 
diabetes that occurs suddenly and has little warning, Type II diabetes develops over a 
number of months to years and can be prevented by changing dietary habits and activity 
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levels. In the overweight or obese state the tissues become insensitive to insulin. 
Maintaining a healthy weight encourages insulin sensitivity at the target tissues requiring 
less insulin secretion. Exercise resensitizes the tissues to insulin by increasing their 
glucose requirements. With inactivity the cells downregulate the expression of their 
insulin receptors due to the decreased need for glucose. When activity levels rise the cells 
begin expressing insulin receptors to meet their increased energy demands. Diet and 
exercise can prevent Type II diabetes in nine out of ten cases of the disease from 
progressing from insulin resistance to diabetes (2). 
Type II diabetes is a serious health problem that has been increasing in incidence 
(3). At least 180 million people in world currently have diabetes (3). Type II diabetes 
accounts for more than 90% of all diabetes cases (3). If left untreated, Type II diabetes 
progresses to an insulin-dependent state and can be complicated with neuropathy, kidney 
failure, cardiovascular disease, blindness, and other conditions (4). As the disease 
progresses from insulin resistance to overt Type II diabetes, a loss in β-cell mass occurs 
that makes it difficult for the patient to respond to fluctuations in blood glucose levels. To 
compensate for insulin resistance and decreased β-cell mass, the remaining β-cells have 
to synthesize and secrete greater amounts of insulin to regulate blood glucose levels. This 
compounding stress may lead to further β-cell death. Post-mortem, Type II diabetic islets 
of Langerhans often contain amyloid deposits composed of islet amyloid polypeptide 
(IAPP). Originally the association of Type II diabetes with the presence of islet amyloid 
led to the application of the amyloid hypothesis to Type II diabetes. The amyloid 
hypothesis states that amyloid fibrils and plaques are cytotoxic and responsible for cell 
death. The hypothesis was originally applied to the amyloid plaques and fibrils composed 
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of Amyloid-β that are associated with neuronal cell death in Alzheimer’s disease. In 
recent years, a new hypothesis has been suggested, that small oligomeric species of IAPP 
form ion-channels in the membranes of β-cells leading to a decline in cellular 
homeostatis and ultimately cell death. Accordingly, recent research has shown that small 
oligomers and protofibrils are much more toxic than islet amyloid (5-9). Interestingly, the 
appearance of amyloid fibrils actually lags behind disease progression and is not present 
in every case of Type II diabetes. The appearance of small oligomeric species in the 
disease state more closely correlates with the onset of disease symptoms and is a more 
likely cause of β-cell toxicity, because oligomeric species have been shown to be highly 
cytotoxic in cell culture experiments (7-9).  
 
1.2 Overview of the Physiological Role of IAPP 
 Islet amyloid polypeptide (IAPP or amylin) is a 37 amino acid peptide that is 
amidated at its C-terminus and contains a disulfide bridge between cysteine residues 2 
and 7 (figure 1.1). IAPP is co-secreted with insulin from the β-cells in the islets of 
Langerhans in the pancreas. The islets of Langerhans are clusters of cells that are 
involved in coordinated hormone secretion. Several cell types including α, β, δ, ε, and 
PP-cells are found in the islets. α-Cells secrete somatostatin, β-cells secrete insulin and 
IAPP, δ-cells secrete glucagon, ε-cells secrete ghrelin, and PP-cells secrete pancreatic 
polypeptide (10). Insulin and IAPP are costored and secreted from within the same 
secretory granules. Secretion of these two hormone peptides occurs in a coordinated 
manner throughout the islet in response to a rise in blood glucose levels. The role of 
IAPP in humans is currently unknown, but based on murine models IAPP acts to slow 
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gastric emptying, binds to receptors in the brain to promote satiety, and slows digestion to 
help down-regulate blood glucose levels post-prandially (11). 
 
Figure 1.1 IAPP sequence. The physiologically active form of the peptide is IAPP(1-37) 
with a cysteine bridge between residues 2 and 7 and the C-terminus is amidated. 
 
1.3 IAPP Oligomers Are Suggested to be Responsible for β-cell Death 
The formation of extra- and intra-cellular fibrils is characteristic of amyloid 
diseases including type II diabetes, Alzheimer’s disease, Parkinson’s disease, etc. Despite 
the commonality of amyloid fibrils in these disease states, recent evidence suggests that 
oligomeric forms of the amyloidogenic proteins, consisting of a few monomers, may be 
the cause of cellular toxicity rather than fibrillar amyloid species (figure 1.2). Human 
islets exposed to early oligomeric species of IAPP led to the apoptosis of the outer cells 
of the islet within 24-48 hours after exposure (12). Similarly, dispersed mouse islet cells 




Figure 1.2 Possible pathway of oligomerization and permeabilization. The early 
oligomeric species permeabilize the membrane, possibly as a barrel stave as shown here, 
although the toroidal pore mechanism is currently more supported in the literature. 
 
Three main mechanisms of membrane permeabilization are discussed in context 
with IAPP: the carpet mechanism, the barrel-stave ion-channel, and the toroidal pore 
(figure 1.3) (13). Membrane permeabilization by any of these three mechanisms could be 
significant enough to lead to β-cell death, although the exact mechanism for IAPP 
induced β-cell death is currently unknown. The carpet model suggests that IAPP peptides 
bind to the lipid head groups based on electrostatic interactions and disrupt the lipids by 
imposing strain on the membrane. The interaction of the peptide opens up spaces of 
permeation between lipids at the site of binding. The barrel-stave model suggests that 
IAPP peptides oligomerize and then insert into the hydrophobic core of the membrane, 
creating a discrete ion-channel in the membrane that is ion selective. The toroidal model 
involves IAPP binding first to the membrane and then interacting with the head groups of 
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the lipids to induce curvature of the membrane where the lipid thins and bends to form a 
pore with lipid headgroups lining the interior of the pore.  
 
Figure 1.3 Mechanisms of membrane disruption. The mechanism of IAPP membrane 
permeabilization is currently unknown. Three main models have been proposed in the 
literature. 
 
1.4 IAPP, Insulin, and the Secretory Granule 
 Interestingly, the peptide involved in type II diabetes, islet amyloid polypeptide 
(IAPP), is present at milli-molar concentrations in secretory granules prior to secretion. 
At these concentrations, IAPP rapidly fibrillizes in vitro, yet within secretory granules of 
healthy individuals IAPP does not fibrillize. In addition to IAPP, insulin is also present 
within the secretory granules prior to secretion and has previously been shown to inhibit 
IAPP fibril formation in the absence of lipids in vitro. 
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1.5 Thesis Summary 
 Previous studies have shown that the N-terminal 1−19 region, rather than the 
amyloidogenic 20−29 region, is primarily responsible for the interaction of the IAPP 
peptide with membranes. Liposome leakage experiments presented in this study confirm 
that the pathological membrane disrupting activity of the full-length hIAPP is also shared 
by hIAPP(1−19). The hIAPP(1−19) fragment at a low concentration of peptide induces 
membrane disruption to a near identical extent as the full-length peptide. At higher 
peptide concentrations, the hIAPP(1−19) fragment induces a greater extent of membrane 
disruption than the full-length peptide. Similar to the full-length peptide, hIAPP(1−19) 
exhibits a random coil conformation in solution and adopts an α-helical conformation 
upon binding to lipid membranes. However, unlike the full-length peptide, the 
hIAPP(1−19) fragment did not form amyloid fibrils when incubated with POPG vesicles. 
These results indicate that membrane disruption can occur independently from amyloid 
formation in IAPP, and the sequences responsible for amyloid formation and membrane 
disruption are located in different regions of the peptide. 
In addition to the region responsible for membrane permeabilization, we sought to 
identify if the cosecreted peptide, insulin, is involved in inhibiting IAPP from 
permeabilizing the β-cell plasma membrane. Insulin readily binds and inhibits IAPP 
fibrillization, yet we found that insulin had negligible effects on IAPP oligomerization 
and toxicity. Contrary to the expected protective effects, insulin maintains the oligomeric 
species of IAPP in a potentially toxic state that permeabilizes liposomes. Other 
characteristics and components of the plasma membrane may play a role in IAPP's 
toxicity. A liposome composition of 30 mol % anionic lipids or more is necessary for 
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IAPP to permeabilize membranes in vitro (1, 14). The anionic charge of the lipid surface 
may be the key determinant of IAPP binding. 
Large unilamellar vesicles (LUVs) are frequently used as a simplified model of 
the cellular plasma membrane. LUVs are liposomes of approximately 100 nm in diameter 
with a bilayer encapsulating an internal aqueous cavity. They can be composed of any 
number of lipids or lipid mixtures depending on the desired conditions. The mol % of 
cholesterol incorporated into LUV membranes determines the fluidity of the membrane 
which affects the ability of IAPP to permeabilization the LUV membranes. As 
cholesterol is increased, membrane permeabilization decreases. Cholesterol appears in 
vitro to inhibit IAPP permeabilization, possibly by filling the interstitial spaces between 
the lipid acyl tails and eliminate space for peptide insertion. 
 
Figure 1.4 IAPP permeabilizes LUVs as measured by dye leakage. Dye leakage 
experiment with quenched carboxyfluorescein encapsulated inside the LUV. Upon 
addition of the peptide, the peptide binds and permeabilizes the LUV releasing 
carboxyfluorescein, which allows it to fluoresce. 
 
Most studies in the literature to date have focused on IAPP peptide binding at the 
lipid interface without identifying if the binding also destabilizes or permeabilizes the 
lipid membrane. We used a dye leakage experiment as a measure of membrane 
permeabilization (figure 1.4). Peptide binding to the lipid membrane may or may not 
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induce membrane permeabilization, but it is expected that the toxic oligomeric species 
permeabilizes the β-cell plasma membrane. We wanted to observe permeabilization, 
which is more representative of toxicity than peptide binding, with our model lipid 
membranes in vitro. We used permeabilization as a model measure of toxicity. IAPP lipid 
binding has been well characterized in the literature, but has not previously been 
connected with permeabilization. We sought to determine the region of IAPP necessary 
for membrane binding and permeabilization, whether IAPP permeabilizes in the presence 
of inhibitory insulin and the effect that cholesterol has on the ability of IAPP to 
permeabilize LUVs. 
CHAPTER II 
The Toxic Oligomer Hypothesis Is Supported by a Membrane Permeabilizing 
Nonamyloidogenic Fragment of IAPP 
 
2.1 Introduction 
 Islet amyloid is a deposit composed of islet amyloid polypeptide (IAPP) in the 
form of proteinaceous plaques and fibrils deposited in the islets of Langerhans of the 
pancreas and is a hallmark of type II diabetes in humans. The islets of Langerhans are 
clusters of approximately 100,000 cells that primarily function to secrete peptide and 
protein non-steroid hormones like insulin, IAPP, and glucagon. The prevalence of islet 
amyloid in the disease state and the increase in the presence of amyloid as the disease 
progresses has led to the assumption that the islet amyloid is in some way responsible for 
the progression of Type II diabetes (15). Prior to extensive examination, research initially 
appeared to support the hypothesis that fibrils and plaques are responsible for Type II 
diabetes. In vitro experiments of rat IAPP (rIAPP), which is nonamyloidogenic due to a 
difference in the amino acid sequence from that of human IAPP, have shown that it is 
non-toxic, which is consistent with the finding that rats do not spontaneously develop 
Type II diabetes (16). This putative link between β-cell death and amyloid formation has 
in turn led to numerous mechanistic fibril formation studies (17-20). However, fully 
formed IAPP fibrils of the toxic human form have since been shown to be relatively inert 
and have little cytotoxic effect on β-cells (5, 6). This finding is in common with other 
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amyloidogenic peptides; the fibrils exhibit relatively little cytotoxicity in comparison 
with earlier species of aggregation (7-9). 
Also present early in the aggregation of IAPP are small oligomeric species. 
Instead of mature fibrils and plaques being responsible for cytotoxicity, these small 
oligomeric species of IAPP may be the culprits. Small oligomeric species of other 
amyloid peptides have been implicated in membrane permeabilization, through either ion 
channel formation or a nonspecific disruption of the membrane (7, 12, 21-23). Whether 
these oligomers form directly on-pathway (24) as precursors to fibril formation or are off-
pathway is unknown (5, 8, 9, 25). The nature of the cytotoxic oligomer is transitory, 
which could fit either pathway of formation. Part of the difficulty in answering this 
question is due to the fact that fibrils rapidly form in the sample to create a heterogeneous 
mixture of species that obscures the identity of any single species. 
 Fragments of IAPP that consist of separate functional regions have been used 
frequently to simplify the analysis of the function of amyloid peptides and to identify 
regions that are necessary for cytotoxicity and amyloidogenesis. Two main regions have 
been identified as responsible for the aggregation of IAPP: IAPP20−29 and IAPP30−37 (26). 
Variations in these sequences have been shown to inhibit amyloid formation analogous to 
that seen in rIAPP (16, 25, 27, 28). Unfortunately, even though IAPP20−29 and IAPP30−37 
have a strong tendency to form amyloid, the toxicity of these peptides appears to be less 
than the full-length peptide (6, 29) Likewise, we wanted to study the ability of the peptide 
to bind and permeabilize our model membrane system. Understanding the interaction of 
amyloid peptides with lipid membranes is crucial to understanding how IAPP leads to β-
cell death. The interaction, as well as the catalysis of toxic oligomers at the membrane, is 
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critical to understanding amyloid diseases (30). The IAPP20−29 fragment is 
amyloidogenic, but has a much lower affinity for phospholipid membranes in comparison 
to the full-length peptide (27, 28). This may be due partially to the charge of the peptide 
at the N-terminus. 
 Previously, it has been shown through lipid monolayer expansion experiments, 
infrared reflection-absorption spectroscopy, and fluorescence anisotropy that the N-
terminus of IAPP is primarily responsible for membrane binding (1, 27, 28, 31). The 
IAPP1−19 fragment does in fact insert more readily than the full-length peptide (27, 28). 
Here we show that the N-terminus of IAPP1−19 can disrupt synthetic lipid vesicles to a 
similar extent as the full-length IAPP peptide. In addition, IAPP1−19 accomplishes this 
without the ability to form amyloid, making it a prime model to study the process of 
IAPP membrane disruption and permeabilization. 
 
2.2 Material and Methods 
 
2.2.1 IAPP Preparation 
 Thioflavin T, DMSO, HFIP, and carboxyfluorescein were obtained from Sigma-
Aldrich; POPG and POPC were purchased from Avanti (Alabaster, AL); Full-length 
human IAPP with the C-terminus amidated (>95% purity) was obtained from Anaspec 
(San Jose, CA). The IAPP1−19 and IAPP20−29 peptides were synthesized using standard 
FMOC (9-fluornylmethoxycarbonyl) methods. A PAL-PEG resin was used to provide an 
amidated C-terminus, and standard FMOC reaction cycles were used. The first residue 
attached to the resin, every β-branched residue, and every residue immediately following 
 12
a β-branched residue were double coupled. Peptides were cleaved from the resin using 
standard trifluoroacetic acid protocols and purified using a reversed-phase C18 column 
with an acetonitrile/water gradient and trifluoroacetic acid as an ion-pairing agent. The 
hIAPP20−29 peptide was synthesized as described above but with both an amidated C-
terminus and an acetylated N-terminus. After synthesis, the crude hIAPP1−19 peptide was 
subjected to air oxidation to form the disulfide bond. The identity of the hIAPP1−19 and 
hIAPP20−29 sequences and formation of the disulfide bond for hIAPP1−19 was verified by 
electrospray mass spectroscopy. Peptide purity was measured as greater than 95% by 
analytical HPLC. 
 
2.2.2 LUV Preparation  
 POPG LUVs were prepared for dye leakage and circular dichroism (CD) 
experiments by first dissolving the powdered POPG lipids to 20 mg/ml concentration in 
chloroform. The chloroform solvent was then removed from the lipids by first 
evaporating it under a stream of N2 gas, which deposits a thin lipid film on the walls of a 
glass test tube. The sample was then dried under a vacuum overnight to remove residual 
solvent. Then the appropriate buffer was used to rehydrate the lipid film creating 
multilamellar vesicles (MLVs) with a 40 mg/ml concentration. Ten freeze-thaw cycles 
were used to equilibrate the buffer and vesicles. LUVs were made from the MLVs by 
extruding the sample through a 100 nm polycarbonate filter in an extruder 21 times 
(figure 2.1). To prepare the LUVs for dye leakage experiments, the lipid film was 
rehydrated with 50 mM NaPi buffer containing 40 mM carboxyfluorescein at pH 7.5. 
Carboxyfluorescein not encapsulated in the LUVs was removed via size exclusion 
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chromatography with a PD-10 column (Amersham Pharmacia Biotech, Uppsala, 
Sweden). The concentration of the phospholipids were determined according to the 
Stewart Method (32). Rehydrated LUV solutions were prepared and used prior to each 
experiment to avoid lipid degradation. 
 
Figure 2.1. Extruder assembly. The extruder is assembled with all of the parts A 
through G in the order shown above. (Step 1) After assembly, the polycarbonate filter is 
hydrated with the addition of the sample buffer and (Step 2) extruded through the 
membrane from side to side a few times and then discarded. (Step 3) LUVs are added to 
the syringe and (Step 4) extruded from side to side. (Step 5) Extrusion is complete upon 
the 21st extrusion, which ends the extrusion on the opposite side to the starting position. 
Ending on the opposite side prevents contamination of multilamellar LUVs that failed to 





2.2.3 CD Spectroscopy  
 IAPP(1−37) and IAPP(1−19) were lyophilized and dissolved for 1 h in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) to prepare a 4 mg/ml peptide solution. Aliquots were re-
lyophilized with HFIP and then solubilized for the experiment in either 10 mM NaPi 
buffer, pH 7.3, or 10 mM NaPi buffer, 150 mM NaF, pH 7.3. After resolubilization, the 
peptide solutions were briefly vortexed, sonicated for ~15 s, and transferred to a 1 mm 
path-length cuvette. An initial CD spectral scan of the hIAPP solution was made prior to 
the addition of POPG vesicles. POPG vesicles were prepared as a 40 mg/ml stock 
solution and then were added to the IAPP solution to a final concentration of 400 μM 
LUV concentration. The spectra were then measured from 190-260 nm at 1nm intervals 
at a 50 nm/min scanning speed, and with a 5 nm bandwidth. Each spectrum was an 
average of four accumulations after subtracting the baseline spectrum of buffer, vesicles, 
and cuvette without the presence of the peptides. The experiments were conducted at RT. 
The CONTINLL option in CDPRO was used to estimate the secondary structure of the 
peptides with SMP56 (13 membrane proteins and 43 soluble proteins) used as the basis 
set (33). Peptides like IAPP exist in a number of conformational states and have a 
tendency to adsorb to quartz and other surfaces. The results of this analysis of the 
secondary structure of IAPP by CD must be treated cautiously as the basis sets were 
developed for large proteins and the applicability of the analysis, for short peptides that 
oligomerize and aggregate is undetermined. Because of these complicating factors in the 
qualitative analysis we listed the approximate secondary structure value instead of the 
exact secondary structure of the peptide. To support our conclusions about amyloid 
formation we used two additional techniques (thioflavin T binding and electron 
 15
microscopy) to verify of the formation amyloid fibrils. The conformational change of the 
IAPP(1-37) peptide observed with ThT and CD spectroscopy occurred on a similar 
timescale and in agreement with previous values reported in the literature (31). 
 
2.2.4 Dye Leakage Assay 
 IAPP(1-37) and IAPP(1-19) stock solutions were dissolved in HFIP and lyophilized 
as described under the CD spectroscopy methods. A concentrated peptide stock solution 
was prepared at 10 mg/ml in pure DMSO. At each data point, the baseline fluorescence 
of the POPG LUV mixture (containing unlabeled LUVs and LUVs with 
carboxyfluorescein encapsulated inside) was measured for 15 s. The fluorescence of the 
baseline is relatively stable with only slight changes due to the slow process of dye 
leakage. After recording the baseline, an aliquot of the DMSO-prepared peptides were 
added to the lipid mixture at 250 nM or 1 μM and measured at 100 s, which allowed 
sufficient time for the IAPP to bind and permeabilize the LUVs. The dye leakage 
plateaued at approximately 100 s, which was thus determined to be an acceptable 
stopping point for each data point. Triton X-100 detergent was then added to the sample 
to 0.2% as a measure of the total fluorescence of the caboxyfluorescein within the 
sample. The % dye leakage was calculated according to eq. 2.1: 









  (eq. 2.1) 
 
The dye leakage was performed at RT with 50 mM NaPi buffer, pH 7.5, and was 




2.2.5 Thioflavin T Fluorescence  
 Peptide and LUVs (27.5 µM peptide, 440 µM lipid) were prepared as described 
for the CD experiments. Thioflavin T (ThT) stock was prepared to 250 µM and added to 
the sample at a final concentration of 25 µM. The ThT was excited at 450 nm and the 
fluorescence emission was measured at 486 nm. The relative fluorescence intensity was 
plotted over the timecourse of the experiment. The ThT t1/2 value for the measure of fibril 
growth was calculated as the time point at which the fluorescent intensity was one-half of 
the maximum intensity. 
 
2.2.6 Electron Microscopy 
 IAPP(1-37) was incubated for 7 days, IAPP(1-19) was incubated for 15 days, and the 
control vesicles without peptide were incubated for 15 days prior to preparing the EM 
grids. Formvar-coated copper grids (Ernest F. Fullam, Inc., Latham, NY) were incubated 
with 10 μl aliquots of peptide sample for 2 min, washed with 10 µl of deionized water 
twice, and then negatively stained with 2% uranyl acetate for 90 s. The samples were 
imaged with a Philips CM10 Transmission Electron Microscope. 
2.3 Results and Discussion 
 
2.3.1 IAPP(1-19) Binds and Permeabilizes LUVs, yet Does Not Form Amyloid. 
 To measure the extent of membrane permeabilization induced by IAPP(1-19) and 
IAPP(1-37), large unilamellar vesicles (LUV) of POPG (1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho-rac-(1-glycerol)) were made to measure the leakage of carboxyfluorescein 
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dye as a measure of permeabilization (i.e. toxicity) (Figure 2.2). At 250 nM peptide 
concentrations, IAPP(1-19) rapidly permeabilized the LUVs almost identically to the full-
length peptide, IAPP(1-37). At a higher concentration of peptide (1 μM), IAPP(1−19) is more 
effective than IAPP(1-37) at inducing membrane disruption, most likely due to the full-
length peptide quickly aggregating to inert fibrils above the critical concentration for 
fibril formation. The critical concentration varies based on buffer conditions but is 
approximately 1 µM in our experiments. IAPP(20-29) is an amyloidogenic fragment that 
quickly forms amyloid fibrils, yet did not induce membrane permeabilization (Figure 
2.2). 
 To investigate the relationship between amyloid fibril formation and membrane 
disruption by IAPP(1-37) and the IAPP(1-19) fragment, conformational changes of the 
peptides associated with membrane binding and fibril formation were measured by CD in 
both low (10 mM phosphate buffer) and high (10 mM phosphate buffer and 150 mM 
NaF) ionic strength solutions. The secondary structures of both peptides in solution are 
similar initially (figure 2.3), as well as in the presence of POPG LUVs (figure 2.4). 
IAPP(1-19) appears completely unstructured in solution (Figure 2.3), and IAPP(1-37) appears 
primarily unstructured in conformation (Figure 2.3A). However, at a high ionic strength 
IAPP(1-37) contains a small amount of β-sheet structure shown by a greater minimum at 








Figure 2.2. Peptide induced dye leakage of carboxyfluorescein from POPG LUVs. A 
constant concentration of 1.5 µM of carboxyfluorescein containing POPG LUVs along 
with the listed concentration of dye-free POPG LUVs were added to each peptide sample. 
(A) The LUVs were added to 250 nM IAPP(1−19) or IAPP(1−37). (B) The LUVs were added 
to 1 mM IAPP(1−19), IAPP(1−37), or IAPP(20-29). The fraction of dye leaked was recorded at 
100 s. The buffer was 50 mM NaPi, pH 7.5. The experiments were conducted in triplicate 


































































Figure 2.3. CD secondary structures of IAPP(1−19) and IAPP(1−37) at high and low 
ionic conditions without LUVs. (A) Spectra of IAPP(1−19) (black line) and the IAPP(1−37) 
(red line) peptides at low ionic strength buffer (no salt, 25 µM NaPi buffer, pH 7.3) and 
(B) peptides at a high ionic strength buffer (150 mM NaF, 25 µM NaPi buffer, pH 7.3). 
IAPP(1−37) exhibits lower solubility at a higher ionic strength. 
 
With the addition of POPG LUVs, IAPP(1-37) and IAPP(1−19) both adopt a primarily α-
helical structure with the characteristic minima at 208 and 222 nm (34). IAPP(1−19) 
remained stable in this conformation for at least 17 h (Figure 2.4A). After 17 h, 
aggregation of the lipid vesicles was visible to the naked eye and the CD signal 
hIAPP




diminished in intensity without altering shape. IAPP(1-37) previously has been shown to 
facilitate the aggregation of liposomes at a low ionic strength (35). The CD signal after 
56 min showed no evidence of the β-sheet structure that is indicative of amyloid fibril 
formation. On the other hand, the IAPP(1-37) peptide showed a conformational change 
from a predominantly α-helical structure to a β-sheet structure indicative of amyloid fibril 
formation within 40 min after the addition of POPG liposomes (Figure 2.4B). With high 
ionic strength conditions more similar to the physiological range (150 mM NaF), 
IAPP(1−19) remained stable in an α-helical conformation for at least 13 days without a 
decrease in the CD signal intensity or the aggregation of the LUVs (Figure 2.5A). IAPP(1-
37) by contrast, showed a conversion of the initial α-helical structure to a β-sheet 
conformation indicative of amyloid fibril formation (Figure 2.5B). The Thioflavin T 
(ThT) fluorescence measured in the presence of POPG LUVs revealed a t1/2 for IAPP(1-37) 
amyloid fibril formation as 64 min (3840 s). This value of 64 min is similar to other 
reports in the literature (Figure 2.6) (36). IAPP(1−19) did not induce an increase in the ThT 
fluorescence over the duration of the experiment, indicating a lack of amyloid fibril 
formation for this peptide. ThT itself is known to not inhibit amyloid fibril formation of 







Figure 2.4. CD spectra of IAPP(1−19) and IAPP(1−37) at low ionic strength in the 
presence of POPG LUVs. (A) IAPP(1−19), 400 µM POPG LUVs (B) IAPP(1−37), 400 µM 
POPG LUVs. The buffer solution (no salt, 25 µM NaPi buffer, pH 7.3) was measured as a 






Figure 2.5. IAPP(1-37) undergoes a structural change to β-sheet structure, while 
IAPP(1-19) does not. CD spectra of IAPP(1−19) and IAPP(1−37) at high ionic strength (150 
mM NaF) and in the presence of POPG LUVs. (A) IAPP(1−19) (B) IAPP(1−37). The buffer 
solution (150 mM NaF, 25 µM NaPi buffer, pH 7.3) was measured as a function of time 





Figure 2.6. IAPP(1-19) does not form amyloid. Thioflavin T (ThT), an amyloid specific 
dye, binds and fluoresces in the presence of hIAPP(1−19) and full-length hIAPP measured 
by fluorescence. IAPP(1-37) or IAPP(1-19) were incubated at 25 µM with 400 µM of POPG 
LUVs and  25 µM ThT. 
 
 To confirm the absence of IAPP(1−19) amyloid fibrils in the CD experiments, 
aliquots at the final timepoint were taken and negatively stained for transmission electron 
microscopy (TEM). The electron micrographs of the IAPP(1-37) sample containing POPG 
LUVs showed amyloid fibrils branching out from the LUVs (Figure 2.7A). Remarkably, 
amyloid fibrils were not detected with IAPP(1−19), which confirms the absence of amyloid 
fibril formation for IAPP(1−19) (Figure 2. 7B). 
 Related N-terminal IAPP fragments, like IAPP(1-18) at 2.14 mM, an extremely 
high peptide concentration, have shown a weak ability to form amyloid (26, 36). 
However, FTIR spectroscopy showed that the amyloid fibrils that were detected by TEM 
were only a minor fraction of the IAPP(1-19) sample. The self-association of the amyloid 
fibrils formed from IAPP(1−19) appeared to be much less than the self-association of 
amyloid fibrils formed from the IAPP(1-37) peptide. Additionally, the IAPP(8−20) amino 
acid sequence of IAPP has also been shown to be weakly amyloidogenic (26). 
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Nevertheless, IAPP8−20 and IAPP1−19 fragments have several important differences 
between them. The disulfide bridge between cysteine residues 2 and 7 conformationally 
restrict this region of IAPP from adopting the β-sheet conformation and may alter the 
amyloidogenicity of the entire peptide (37, 38). The studies on both IAPP(1-18) and 
IAPP(8-20) were done in solution, without the presence of lipid vesicles. Lipid vesicles 
may bury hydrophobic residues that are exposed in solution within the membrane and 
would be expected to alter the energetics of amyloidogenesis. 
 
 
Figure 2.7. IAPP(1-19) does not form visible amyloid fibrils by TEM. Electron 
Micrographs of IAPP peptides incubated with POPG LUVs (A) IAPP(1−37) incubated with 
POPG LUVs for 7 days. Amyloid fibrils can be seen emanating from the peptide 
engulfed POPG LUVs. (B) IAPP(1−19) incubated with POPG LUVs for 15 days. No 
amyloid fibrils were visibly detected. (C) POPG LUVs incubated without peptide for 15 
days (scale = 500 nm). 
 
2.3.2 Amyloid Fibril Formation and Membrane Disruption Are Separate Processes 
Localized in Two Distinct Regions of IAPP 
 Our results indicate that IAPP amyloid fibril formation is not necessary for the 
peptide to permeabilize membranes. As established in the literature, amyloid fibrils 
themselves are not especially toxic (5, 6), but it is debatable whether amyloid formation 
is necessary for the generation of small toxic oligomers and the membrane 
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permeabilizing activity of amyloid peptides. Our results suggest that the membrane 
disrupting activity of IAPP can be achieved irrespective of amyloid formation and occurs 
primarily as a result of other factors not necessarily related to amyloidogenesis (39). One 
of the strongest pieces of evidence supporting the amyloid hypothesis instead of the 
oligomer hypothesis is the lack of a cytotoxic response from the nonamyloidogenic rat 
IAPP. However, Knight et al. have recently shown that the nonamyloidogenic rIAPP 
does have the ability to disrupt membranes under certain conditions (14). The detection 
of a small degree of β-cell apoptosis in diabetic rats also supports the conclusion that rat 
IAPP can be toxic, albeit to a lesser degree than the human IAPP (40). The binding of 
IAPP to the membrane is cooperative and dependent on the formation of small oligomers 
on the surface of the membrane. In addition to being unable to form amyloid fibrils, rat 
IAPP is less effective at forming the small oligomers necessary for membrane binding 
than is human IAPP (14). The difference in toxicity between the rat and human versions 
of IAPP therefore may be largely due to a difference in the formation of these small 
oligomers rather than the inability of rat IAPP to form amyloid fibrils. 
 It is likely that several processes that lead to cell death are simultaneously 
operational in vivo, some of which are dependent on the formation of amyloid fibrils and 
others that are not. The instability of the proposed toxic intermediates, a particularly 
acute problem for the IAPP peptide due to its extremely fast rate of aggregation, 
considerably complicates analysis. The IAPP(1−19) fragment, which does not form 
amyloid fibrils but disrupts membranes to a similar extent as that for the IAPP(1-37) 
peptide, will be a useful tool to disentangle this complex process. 
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 Previous studies of the secondary structure of IAPP have shown that residues 1−7 
and 19−37 are likely to be disordered after the peptide initially binds to the membrane 
(1). Packing density arguments suggest that the N-terminal segment of the IAPP peptide 
(residues 1−18) adopts a transmembrane orientation, while the C-terminal region is 
believed to lie outside the membrane in a disordered state (figure 2.8) (1, 14, 30). The 
formation of secondary structure in the C-terminal region is expected to drive the process 
of amyloidogenesis in the full-length IAPP peptide (14, 41). The IAPP(1−19) peptide 
shows a similar amount of helical content to that of IAPP(1-37) (Figure 2.3A). However, 
the N-terminal segment (residues 1−7) is conformationally constrained from adopting a 
secondary structure by the presence of a disulfide bond between residues 2 and 7 (37, 
38). Without the formation of an additional secondary structure as a driving force, the 
amyloidogenic propensity of IAPP(1−19) is expected to be far less than that of IAPP(1-37). 
Nevertheless, the amphipathic helical structure of the full-length peptide implicated in 
membrane-disrupting properties is retained in IAPP(1−19) (14). 
 
Figure 2.8 Cartoon of IAPP(1-19) and IAPP(1-37) showing a possible mechanism of 
peptide action, with only IAPP(1-37) forming fibrils. IAPP(1-19) binds and permeabilizes 
anionic LUVs without forming amyloid fibrils. IAPP(1-37) binds, permeabilizes, and forms 




 Because of the stability of the IAPP(1−19) fragment in membranes, we expect that it 
will be useful as a model system to study the membrane disrupting effects of IAPP and 
other amyloid peptides, using high-resolution techniques such as solid-state NMR 




Insulin Stabilizes the Membrane Permeabilizing Species of Islet Amyloid 
Polypeptide 
3.1 Introduction 
While the exact causes of β-cell death in overt Type II diabetes are largely 
unknown, there is strong evidence that the human Islet Amyloid Polypeptide (IAPP) 
plays an important role (42-44). It is well known through in vitro, tissue culture, and 
transgenic animal studies, as well as postmortem clinical examinations, that large β-sheet 
aggregates of IAPP, known as islet amyloid, are often associated with the development of 
Type II diabetes (42-44). Similar extracellular proteinaceous deposits composed of large 
aggregates of proteins in a characteristic cross β-sheet conformation have been found in 
an increasing number of pathologies, including Alzheimer’s, Huntington's, and 
Parkinson’s disease, among many others (42, 43). An aggregated (but not necessarily 
fibrillar) form of the peptides and proteins implicated in these amyloid associated 
diseases have been found to disrupt the integrity of cellular membranes to varying 
degrees: allowing the uncontrolled influx of calcium into the cell, subjecting the cell to 
membrane-associated oxidative stress, and triggering the initial stages of apoptosis. 
The relevant factors that trigger IAPP aggregation and pancreatic β-cell 
membrane disruption in some individuals but not others are elusive, as the pathology of 
IAPP aggregation occurs most often with the wild-type peptide and is not associated with 
mutations of the IAPP sequence, except for the rare S20G polymorphism (45-48). Since 
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the wild-type IAPP is both aggressively amyloidogenic and toxic at low (<5 µM) 
concentrations in vitro, yet is stored in the secretory granule of β-cells at concentrations 
orders of magnitude higher (0.8-4 mM) without apparent dysfunction in non-diabetic 
individuals, it is unknown how IAPP is regulated to control both its aggregation and its 
inherent cytotoxicity. In fact, considering the high toxicity of IAPP in vitro, it may be 
more relevant to question what stops IAPP from attacking β-cells in healthy individuals, 
rather than what triggers IAPP aggregation and toxicity in diabetics. 
Insulin, which is copackaged and cosecreted with IAPP from within the secretory 
granule, has emerged as a possible regulator of IAPP fibrillogenesis. Several studies have 
reported that insulin can inhibit the formation of amyloid by IAPP in solution (49-53), 
although this effect was not consistent in all studies, and some reported either little 
change or a slight increase in the rate of fibril formation at lower ratios of IAPP to insulin 
(54). Moreover, the relationship between amyloid fibril formation and β-cell toxicity is 
not entirely obvious. Mature amyloid fibrils composed of IAPP have little toxicity to cells 
in culture (5, 6, 12, 21, 55). Furthermore, amyloid formation is not necessarily correlated 
with the loss of β-cell mass in Type II diabetes in all cases. Deposits of islet amyloid 
have been found in both non-diabetics and Type II diabetics, yet some diabetics present 
no amyloid deposits in the advanced stages of the disease (56, 57). In addition, the 
appearance of islet amyloid is often spatially separated from the site of β-cell apoptosis 
and the onset of symptoms correlates poorly with the initial appearance of islet amyloid 
(58-60). Instead of amyloid fibrils, the formation of small oligomeric species that form 
either in association with the plasma membrane or in solution are a critical step in 
amyloid-induced apoptosis (61-68). Although the kinetics of these species have been 
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intensely studied, relatively little is known about the equilibrium between oligomer states 
in this process of forming the small oligomeric species of IAPP. 
In contrast to the effect of insulin on IAPP amyloid formation, the effect of 
insulin on IAPP-induced membrane disruption and cell toxicity has been relatively 
unexplored. The use of compounds that bind to the end-stage of aggregation, that consists 
mostly of amyloid fibrils are largely unsuccessful in reducing the toxicity of these 
amyloidogenic proteins, most likely due to the low toxicity of the end-stage amyloid 
fibrils (5, 69). Other compounds have been shown to actually increase the toxicity of 
amyloid proteins by inhibiting the formation of the relatively inert amyloid fibrils, while 
increasing the amount of peptide in the early oligomeric and more toxic forms. An 
example of this is clusterin (apolipoprotein J), a protein found in Alzheimer’s disease 
plaques, that binds and inhibits amyloid-β1-42 fibrillization, yet at the same time increases 
the cytotoxic amyloid-β1-42 species (61, 70, 71). Conversely, other inhibitors can block 
amyloid induced toxicity without affecting or even increasing amyloidogenesis. 
The purpose of this research was twofold: (1) to further understand the separate 
functions of IAPP amyloid formation and membrane binding and (2) to determine if 
insulin inhibits IAPP not only from fibrillization but also from forming the toxic 
oligomeric species. We show that the binding of IAPP to the membrane and IAPP-
induced membrane disruption are present even when amyloid formation is blocked by 
coincubation with insulin, which lends support to the oligomeric hypothesis of β-cell 
death. Thus, IAPP has the ability to permeabilize membranes without forming amyloid, 




3.2 Material and Methods 
 
3.2.1 IAPP and Insulin Preparation 
Human IAPP was purchased from Anaspec Inc., recombinant human insulin 
expressed in yeast was purchased from Sigma-Aldrich. The IAPP peptide used in this 
study was amidated at the C-terminus like the natural peptide. Preformed aggregates in 
both peptides were solubilized by first dissolving the peptide in a 75% acetonitrile/water 
solution at a concentration of 1 mg/ml. The peptides were then lyophilized, and the 
lyophilized powder was redissolved in hexafluoroisopropanol (HFIP) at a concentration 
of 2-4 mg/ml. HFIP was removed by lyophillization overnight at high vacuum (72). The 
peptide was first dissolved in pure water to a concentration of 25 µM in siliconized 
eppendorf tubes and then diluted with 2x buffer to create the final working solution (final 
buffer composition: 100 mM NaCl, 10 mM sodium phosphate, pH 7.4) (73). 
 
3.2.2 Liposome Preparation 
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)] (POPG) and 1-
Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (POPC) dissolved in chloroform were 
purchased from Avanti Inc. (Alabaster, AL). To make liposomes, chloroform lipid stocks 
were dried with a stream of nitrogen and then placed under vacuum overnight to remove 
residual solvent. The lipid films were then rehydrated for 1-2 hours with 10 mM NaPi, 
buffer at pH 7.4 containing 100 mM NaCl. The rehydrated lipids were vortexed and then 
subjected to 8 freeze-thaw cycles. The resulting multilamellar vesicles were extruded 21 
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times through two 100 nm polycarbonate Nucleopore membrane filters (Whatman) to 
create unilamellar vesicles. 
For liposomes with dye encapsulated inside, the vesicles were created as above 
except the buffer also contained 50 mM 5(6)-carboxyfluorescein. Free dye was separated 
from the lipid encapsulated dye by running the samples through a 10 mL Sephadex G-50 
gel filtration column (Sigma-Aldrich). Lipid concentrations were determined using the 
Stewart method (32). 
 
3.2.3 Circular Dichroism 
Circular dichroism was performed using a J-715 spectropolarimeter (Jasco, 
Easton, MD) at RT with a 1 mm pathlength cuvette. IAPP, IAPP/Insulin mixtures and 
liposomes were prepared as above except NaF was used in place of NaCl. Each spectrum 
was obtained from the average of 10 accumulations between 190-260 nm. Spectra were 
collected at 50 nm/min, with a response time of 2 s and a bandwidth of 5 nm. Spectra of 
the buffer, liposomes, and cuvette were subtracted from the IAPP spectra. To prevent 
masking of the IAPP signal by insulin, the insulin signal was also subtracted from the 
spectra of IAPP and insulin mixtures 
 
3.2.4 Dye Leakage 
IAPP or IAPP/insulin (25 µM) was preincubated for the indicated amount of time 
and then diluted to 1 µM immediately before addition to a 200 µM mixture of LUVs (195 
µM empty POPG vesicles, 5 µM dye-encapsulated POPG vesicles). The fluorescence 
was recorded for the LUV mixture prior to the addition of the peptide and subtracted 
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from the sample. At the completion of dye leakage, the total signal was normalized by 
adding Triton-X detergent to 0.2% v/v to permeabilize any remaining intact LUVs with 
encapsulated dye. Dye leakage was plotted according to equation 2.1. 
 
3.2.5 Glutaraldehyde Crosslinking and Western Blotting. 
IAPP (25 µM) and IAPP/insulin (25 µM: 25 µM) were incubated at room 
temperature with POPG/POPC LUVs (200 µM) in 100 mM NaF, 10 mM NaPi, pH 7.4 
for the indicated times. After incubation, 0.01% (v/v) glutaraldehyde was added to 
initiate cross-linking at each time-point. The cross-linking reaction was allowed to 
continue for 30 min and was then quenched by the addition of 100 mM lysine. 3x SDS-
PAGE loading buffer was then added and the samples were placed on a heat block at 
90°C for 2 min. The samples were electrophoresed on 10-20% (w/v) polyacrylamide SDS 
Tris-Tricine Ready Gel (Bio-Rad, Hercules, CA), transferred with CAPs transfer buffer 
pH 11.0, immunoblotted on nitrocellulose with rabbit polyclonal α-IAPP antibody 
(Anaspec Inc., San Jose, CA). The primary antibody was visualized with a horseradish 
peroxidase conjugated α-rabbit antibody and ECL (Bio-Rad, Hercules, CA). 
 
3.2.6 Transmission Electron Microscopy 
Samples (10 µL of 25 µM) were incubated for 2 min on Formvar-coated copper 
grids (Ernest F. Fullam, Inc., Latham, NY). The grids were then washed twice with 10 µl 
deionized water and then negatively stained with 10 µl of 2% uranyl acetate for 1.5 min. 




3.2.7 Thioflavin T Assay 
Peptides were initially solubilized with deionized water, 2x buffer was added, and 
then Thioflavin T was added to final concentrations of 25 µM for each peptide with 5 µM 
Thioflavin T. The fluorescence intensity of the ThT mixture was measured with a BioTek 
Synergy 2 plate reader (BioTek, Winooski, VT). 
 
3.3 Results 
3.3.1 Insulin in the Monomeric Form Inhibits IAPP Amyloid Fibril Formation Both in 
Solution and in the Presence of Membranes 
 Human IAPP in solution normally exists in a predominantly random coil 
conformation, but converts into a β-sheet conformation indicative of amyloid fibrils in a 
nucleation-dependent process. Several studies have reported that insulin can inhibit this 
process (49-53), although this effect was not consistent in all studies, and some reported 
either little change or a slight increase in the rate of fibril formation at lower ratios of 
IAPP to insulin(54). Since the effect of insulin on IAPP has been reported to be 
dependent on the oligomeric state of insulin, we have accordingly first tested the effect of 
insulin on the formation of amyloid by IAPP at near neutral pH and at an ionic strength 
approximating the conditions found in the extracellular space. 
 Amyloid fibril formation was measured using the amyloid-specific dye, thioflavin 
T (ThT), which has a large increase in quantum yield upon binding to the cross-beta sheet 
structure characteristic of amyloid fibrils. The growth of fibrils is measured by a relative 
increase in ThT fluorescence intensity often called a relative fluorescence unit (rfu), 
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which is the relative change in fluorescence intensity from the baseline fluorescence. The 
presence of ThT in the reaction mixture does not significantly affect the kinetics of fibril 
formation by IAPP (8, 74). The kinetics of amyloid formation occurs by a nucleation-
dependent process that is characterized by an initial lag phase, where amyloid formation 
is very slow, and rapid formation of amyloid in the later stages after the formation of 
nucleating particles. Fibril formation for IAPP in the absence of insulin occurred after a 
lag time of approximately 1000 minutes, similar to previous reports under similar 
conditions (Fig. 3.1A). In the presence of an equimolar amount of insulin the lag time for 
fibril formation increased dramatically, and significant fibril formation was not observed 
after 7000 minutes, indicating insulin inhibits the formation of amyloid fibrils by IAPP in 




Figure 3.1. Insulin inhibits IAPP fibril formation. Enhancement of thioflavin T 
fluorescence showing fibril formation by IAPP and by (A) IAPP and insulin mixtures and 
by (B) insulin alone. Mixtures of IAPP and insulin form fibrils at a reduced rate. Insulin 
also has the ability to form oligomers and fibrils. 
 
 The inhibitory effects of insulin on IAPP fibrillization in solution was confirmed 
by transmission electron microscopy (TEM). IAPP was incubated alone and with insulin 
at an equimolar concentration (25 μM) for seven days and then negatively stained and 
imaged with transmission electron microscopy (TEM) (Fig. 3.2). In the absence of 
insulin, IAPP fibrillizes extensively to form a meshwork of amyloid fibrils (Fig. 3.2). In 
agreement with the ThT results, TEM indicates IAPP fibrillization is greatly inhibited in 
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a concentration-dependant manner by the presence of insulin (Fig. 3.2B). The few fibrils 
that formed appeared short and fragmented, consistent with a previous report that the 




Figure 3.2. Insulin reduces, but does not fully prevent fibril formation in the 
absence of liposomes. Transmission electron microscopy images of (A) IAPP and a (B) 
1:1 mixture of IAPP/Insulin incubated without liposomes at room temperature and pH 7.4 
for seven days. Fibrils formed in all cases, but the incidence was reduced with increasing 
insulin concentration. 
 
 The interaction of IAPP with insulin in the presence of membranes is less well 
characterized. Binding of IAPP to the membrane converts the peptide to an α-helical 
form at a rate that is rate-limiting for IAPP fibrillogenesis (1, 75). A previous study 
showed an inhibitory effect of insulin on IAPP fibrillogenesis in the presence of LUVs, 
although considerably less than in the absence of membranes (51). However, this study 
used the hexameric, low pH, form of insulin (T6). Accordingly, a similar experiment was 
performed with the addition of LUVs. To differentiate the ability of IAPP to permeabilize 
liposomes on the basis of the LUV charge ratio, IAPP was added to dye-labeled LUVs 
prepared at several different ratios of anionic POPG to zwitterionic POPC (Fig. 3.3). 
IAPP permeabilized the LUVs mixtures until the anionic lipid composition of the LUVs 
was reduced to POPG/POPC molar ratios of 1:3 and 0:4. The effect of monomeric insulin 
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on the ability of IAPP to form fibrils in the presence of the POPG/PC LUVs at neutral pH 
was even more distinct than in solution (Fig. 3.4). IAPP fibrillizes extensively to form a 
meshwork of IAPP fibrils in the presence of LUVs seven days after mixing (Fig. 3.4A), 
yet with an equimolar concentration (25 μM) of insulin coincubated with IAPP we see 
that insulin again strongly inhibits IAPP fibrillization (Fig. 3.4B). Only a few fibrils were 
found in the sample showing that when IAPP is incubated with insulin and LUVs there is 
a greater reduction in fibril growth than without LUVs. 
 
Figure 3.3. IAPP permeabilizes liposomes based on the anionic charge of the lipids. 
The ability of IAPP to permeabilize liposomes decreases as the ratio of zwitterionic 
POPC lipid increases, decreasing the anionic effect of POPG. IAPP was 1 μM and each 
liposome composition totaled 200 μM. The fluorescent reading of the sample was 
recorded at 100 s minus the baseline (without peptide) at 100 s. This value was divided 
by the total fluorescence at 100 s after adding a Triton-x detergent minus the baseline at 




Figure 3.4. Insulin strongly inhibits fibril formation in the presence of POPG/PC 
liposomes. Transmission electron microscopy images of (A) IAPP and (B) IAPP/insulin 
in a 1:1 incubated at 25 µM with 200 µM POPG/PC liposomes at room temperature and 
pH 7.4 for seven days.  
 
 The structural change of IAPP in the presence of POPG/PC liposomes was also 
monitored by circular dichroism (Fig. 3.5). For this experiment, the insulin signal was 
subtracted from that of the IAPP/insulin sample. This procedure allowed a comparison of 
the pure IAPP signals in both the IAPP and IAPP/insulin samples, without the 
contribution of the strong insulin signal (53). A very clear structural change occurred in 
the IAPP sample indicative of β-sheet fibril formation, which was prevented in the 
presence of insulin. As a control, IAPP and IAPP/insulin samples were observed without 
the presence of liposomes (figure 3.6). IAPP in the presence of insulin appears α-helical 
and then precipitates out of solution by 50 h without forming β-sheet structure, which is 
on the same timescale that IAPP sample without insulin and LUVs forms β-sheet 
structure. The effects of insulin on the structural properties of IAPP, without liposomes to 
accelerate the strucutural transition of IAPP to β-sheet structure and without liposomes to 
create a high local IAPP concentration at the membrane surface, appears to inhibit β-
sheet structure, but the resulting data is less clearly discernable than the IAPP samples 






Figure 3.5. Insulin slows IAPP from forming β-sheet secondary structure in the 
presence of POPG/PC liposomes. (A) In the presence of POPG/PC LUVs, IAPP 
undergoes a structural shift from a predominantly random coil structure to a β-sheet 
indicative of around 1 h. (B) IAPP in the presence of insulin and POPG/PC LUVs does 
not undergo a structural transition to β-sheet within 69 h. The components of each signal 
were subtracted, except for the IAPP signal, to compare the effects insulin had on the 
time to β-sheet formation of IAPP. The samples contained 25 μM IAPP (A) or 25 μM 






Figure 3.6. Insulin has little effect on the secondary structural change of IAPP 
without liposomes. (A) IAPP undergoes a structural shift from a predominantly random 
coil structure to a β-sheet structure around 50 h. (B) IAPP in the presence of insulin 
precipitates out of solution by 50 h without forming β-sheet structure. The components of 
each signal were subtracted, except for the IAPP signal, to compare the effects insulin 
had on the time to β-sheet formation of IAPP. The samples contained 25 μM IAPP (A) or 





3.3.2 IAPP Has a Stimulatory Effect on Insulin Amyloidogenesis at Neutral pH 
Monomeric insulin forms amyloid fibrils through the formation of a partially 
unfolded intermediate. Insulin in the absence of IAPP also undergoes an amyloidogenic 
transition with a lag time approximately three times longer than that of IAPP 
(approximately 50 h) (Fig 3.1B). Interestingly, increasing the concentration of insulin to a 
10:1 molar excess over IAPP decreased the lag time relative to the 1:1 mixture of IAPP 
and insulin, indicating the overall rate of amyloid fibril formation increased as the 
concentration of insulin was increased (Fig 3.1B). This effect was not due simply to the 
increase in insulin concentration, as the kinetics of 25 μM and 250 μM insulin solutions 
without IAPP are similar. Although the data is not conclusive, the decrease in lag time 
suggests that IAPP may act to catalyze the amyloidogenesis of insulin. 
 
3.3.3 Insulin Does Not Prevent IAPP-induced Membrane Disruption 
 One of the primary mechanisms of IAPP-induced toxicity is disruption of the 
cellular membrane.(14, 21, 23, 24, 76-80) Our results indicate that insulin strongly 
inhibits fibril formation both in solution and in a membrane environment, in agreement 
with previous reports. However, recent research indicates membrane disruption by 
amyloid proteins and amyloid formation are separate, although related processes, and the 
effect of insulin on membrane disruption, as opposed to amyloid fibril formation, is 
unknown. Accordingly, the ability of IAPP to disrupt model membranes composed of 
either POPG or a 1:1 mixture of POPG/POPC in the presence of insulin was tested using 
a dye leakage assay. In the absence of insulin, IAPP strongly disrupts both POPG (Fig. 
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3.7A) and, to a somewhat lesser degree, POPG/POPC (Fig. 3.7B) vesicles as has been 
previously reported for this peptide (1). 
 Insulin did not block IAPP from permeabilizing the liposomes, despite its 
inhibitory effect on amyloid formation (Fig. 3.7). Insulin also binds membranes and has 
been shown to cause membrane disruption by a similar mechanism under certain 
conditions.(81) As shown in Fig. 3.7, insulin alone had a slight disruptive effect on both 




Figure 3.7. Permeabilization of liposomes by IAPP in the presence of insulin. (A) 
Samples of 1 µM IAPP, 1 µM  IAPP + 1 µM  insulin mixture, and 1 µM  insulin were 
added  to 200 μM of POPG liposomes and monitored for dye leakage over 60 min. (B) 
The same experiment repeated with POPG/POPC dye leakage lipids. Rather than adding 
the peptide at distinct time points of aggregation to new liposomes with encapsulated dye 
(as shown in fig. 3.8), the peptides were added at zero time and monitored for the 
duration of the timecourse. 
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 Since the amyloid form of the peptide is less effective at disrupting cellular and 
artificial membranes than the freshly dissolved peptide, the ability of IAPP to 
permeabilize membranes declines over time as the percentage of amyloid in the sample 
increases. This effect was monitored by adding IAPP (with or without an equimolar 
amount of insulin) to fresh lipid preparations at each timepoint to measure how toxicity 
changes over the course of the experiments (Fig. 3.8). IAPP’s ability to permeabilize 
liposomes in the absence of insulin declines rapidly after 5 hours of preincubation in 
solution before being added to the liposomes, which corresponds with the start of 
exponential fibril growth in solution measured by ThT fluorescence at ~15 hours (Fig. 
3.1A). This result is in agreement with numerous reports that have shown mature amyloid 
fibrils to be non-disruptive to membranes and non-toxic to cells, in contrast to earlier 
forms of the peptide. 
 The presence of insulin changes the influence of IAPP pre-incubation time on 
membrane disruption dramatically. In contrast to the rapid decrease with preincubation 
time seen in the absence of insulin, the ability of IAPP/insulin mixtures to permeabilize 
liposomes declines only slowly over the course of the experiment. The toxicity of a 1:1 
IAPP/insulin mixture does not fully disappear until approximately 300 h when it starts to 
slowly polymerize (Fig. 3.8A), matching the slow decline in permeability over time. 
Insulin at this concentration alone had no ability to permeabilize liposomes or form 
fibrils. At a higher concentration (250 μM or 10x the concentration of IAPP) insulin 
eventually oligomerizes and permeabilizes liposomes after 100 h. (Fig. 3.8B) Insulin 
blocks fibril formation, but is ineffective at blocking oligomer formation and actually 
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maintains the toxicity of the IAPP long past the normal life of the toxic IAPP oligomer 





Figure 3.8. Insulin does not protect against membrane damage and maintains IAPP 
in an active permeabilizing form for a lengthened period of time. Peptides were 
incubated and added to fresh 200 μM POPG liposomes (5 μM POPG liposomes with 
encapsulated dye and 195 μM POPG liposomes) at each timepoint. (A) Dye leakage 
conducted with equimolar concentrations of 1 μM IAPP and 1 μM insulin and (B) 10 × 
insulin concentration showing that when insulin is incubated at high concentrations it is 
capable of forming a toxic amyloid species. To prevent the interference of insulin 
toxicity, insulin was used at low equimolar concentrations to IAPP. 
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3.3.4 Insulin Does Not Prevent the Membrane-catalyzed Formation of Small Oligomeric 
Species 
 Insulin is able to effectively inhibit the fibrillization of IAPP, but has a 
stimulatory effect on vesicle permeabilization by IAPP. A current hypothesis holds that 
membrane disruption by amyloid proteins is not due to the action of amyloid fibrils but 
rather to the action of smaller oligomeric species. The processes for the formation of 
small oligomeric species and amyloid fibrils have been shown to be distinct, and in some 
cases can be uncoupled from each other so that small, toxic oligomers form but not 
amyloid fibrils or vice versa. Glutaraldehyde crosslinking was used to detect the 
populations of small membrane bound IAPP oligomers at a number of time points during 
the membrane-catalyzed aggregation of IAPP (Fig. 3.9). An IAPP specific antibody was 
used to distinguish IAPP oligomers from insulin oligomers. In the absence of insulin, 
bands corresponding to monomers, dimers, trimers and tetramers were detected, along 
with a relatively strong band corresponding to high molecular weight species that exceed 
the resolving power of the gel. A decrease in the intensity of the monomer band and a 
corresponding increase in the oligomer bands can also be detected by comparing the 





Figure 3.9. Cross-linking of IAPP and insulin bound to POPG/POPC LUVs. IAPP 
(25 μM) or IAPP/insulin (25 μM /25 μM) were incubated with POPG/POPC LUVs (200 
μM) at room temperature to allow the peptides to oligomerize. At each timepoint aliquots 
of each sample were removed and crosslinked with 0.01% (v/v) glutaraldehyde. The 
reactions were quenched with the addition of lysine and loading buffer, boiled, and 
separated with SDS-PAGE. The gel was transferred and then immunoblotted with a 
rabbit polyclonal α-IAPP antibody. 
 
 In contrast to its effect on amyloidogenesis (Figs. 3.1-3.4) the addition of one 
molar equivalent of insulin has little effect on the formation of IAPP oligomers (lanes 5-8 
in Fig. 3.9). The western blot of the cross-linked IAPP-insulin complex is similar to that 
of cross-linked IAPP, except the bands corresponding to high molecular weight species 
are absent. In addition, the decrease in the intensity of the monomer band over time is not 
seen in the IAPP-insulin sample. Significantly, the bands are in the same positions for 
samples with and without insulin, indicating that IAPP does not cross-link to insulin 
under these conditions. The absence of a shift in mass in the Western-blot due to cross-
linking to insulin suggests that the membrane-disruptive species are largely composed of 






3.4.1 Insulin Stabilizes IAPP Oligomers and Maintains IAPP Toxicity. 
 Islet amyloid deposits are frequently found in Type II diabetics but only rarely in 
non-diabetics; as a result, the toxicity of IAPP has been proposed by others to be linked 
directly to IAPP amyloid formation (82, 83). Since IAPP is stored together with an excess 
of insulin within the β-cell secretory granules, and several studies have shown the 
inhibitory effect of insulin on IAPP fibrillogenesis, it has been frequently implicitly 
assumed that insulin would also inhibit the inherent toxicity of IAPP (49, 53, 84). 
However, recent experiments on other amyloid proteins have challenged this notion. 
While the extent of amyloid formation in type II diabetes (as well as other amyloid-
associated diseases) is correlated with progression of the disease, amyloid formation by 
itself does not cause pathological dysfunction. In general, however, inhibition of amyloid 
fibril formation is correlated with a concomitant reduction in amyloid toxicity. However, 
notable exceptions to this rule exist. A prime example is the failure of the Aβ antibody to 
prevent toxicity. The anti-amyloid-β1-11 antibody binds and inhibits amyloid-β1-42 
fibrillization, yet at the same time it stabilizes the cytotoxic amyloid-β1-42 species (85). 
Although the antibody inhibited fibril formation, toxicity was not completely prevented. 
The toxicity was somewhat reduced but likely only because the antibody has a partial 
ability to bind to the early oligomeric species in addition to protofibrils and fibrils. Given 
that smaller oligomers of the peptide typically have a much greater toxicity than the 
mature fibrils, inhibitors of amyloid formation may increase the toxicity of the peptides if 
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they do not inhibit the binding of the peptide to the membrane and the formation of small 
oligomers on the membrane. 
 While insulin has been demonstrated to be an in vitro inhibitor of IAPP 
fibrillization, its effects on IAPP membrane disruption and toxicity are less understood. 
To test the impact of insulin on IAPP toxicity, we have observed the ability of insulin to 
inhibit IAPP fibril formation and have tested IAPP’s ability to disrupt membranes in 
model membranes under buffer conditions that approximate the pH and ionic strength 
found after secretion. We found that (a) insulin inhibits only amyloid fibrillization and 
not the formation of small oligomeric species of IAPP on the membrane, (b) IAPP 
rapidly permeabilizes lipid membranes even in the presence of soluble insulin, (c) the 
ability of IAPP to permeabilize membranes decreases rapidly with time as the peptide is 
incubated in solution in the absence of membranes, and (d) insulin permits IAPP to 
continue to permeabilize liposomes far longer than in the absence of insulin as long as 
stoichiometric or excess amounts of insulin are present. Taken together, these results 
show that insulin alone may not have the ability to protect β-cells from IAPP toxicity at 
the site of secretion, and alternate hypotheses should be considered for the mechanism by 
which the cell maintains IAPP in a stable and nontoxic state in non-diabetic individuals. 
 
3.4.2 Insulin Enhances IAPP Membrane Disruption by Inhibiting the Conversion of 
Membrane-active Protofibrillar Species into the Fibril Form 
 Membrane disruption is believed to be one of the primary causes of cell death 
caused by amyloidogenic proteins (77, 80, 86). Among amyloid peptides IAPP is 
somewhat unusual in that the highest amount of membrane disruption is detected 
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immediately after solubilization and then decreases monotonically afterwards (fig. 3.8) 
(22, 87). This is in contrast to most other amyloid proteins in which membrane disruption 
first increases with time as toxic, membrane-binding oligomers form in solution and then 
decreases as the protofibrillar species are converted into relatively inert mature amyloid 
fibrils (62-68, 88-90). The transient nature of the protofibrillar species limits the amount 
of time the β-cell is exposed to the highly toxic protofibrillar species, as IAPP either 
diffuses away from the secretion point where it rapidly decreases to non-aggregating 
concentrations or it is converted to less toxic amyloid fibrils near the secretion point (14, 
31, 91, 92). 
Our results are consistent with insulin inhibiting IAPP fibril formation, but being 
ineffective at blocking the formation of smaller IAPP oligomers both in solution and on 
the membrane. A schematic representation is shown in Fig. 3.10. Insulin inhibits IAPP 
formation both in the absence and presence of membranes (Figs. 3.1-3.2 and 3.4-3.5). 
However, insulin, which blocks fibril formation, prolongs the time-period of IAPP 
toxicity, long past the normal life of the toxic IAPP oligomer in the absence of insulin 
(Fig. 3.8). In the absence of insulin IAPP forms fibrils in solution and the ability of IAPP 
to cause membrane disruption is rapidly reduced after 50 h (Fig. 3.1A and 3.8A). In the 
presence of an equimolar amount of insulin the ability of IAPP to induce membrane 
disruption was maintained for far longer and only decreases slowly after ~ 275 hours 
(Fig. 3.8A). A similar result was obtained with a 10-fold excess of insulin, except the 
toxicity did not decrease after ~ 275 hours, apparently due to the formation of membrane-
disruptive species of insulin itself (Fig. 3.8B). The ability of insulin to suppress the 
formation of large oligomers of IAPP but not small oligomers of IAPP on the membrane 
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was confirmed by time-lapse cross-linking of IAPP and IAPP-Insulin solutions added to 
POPG/POPC liposomes, Small oligomers could be detected in both samples whether 
insulin is present with IAPP or not, but the monomer in the sample with IAPP alone 
quickly disappeared and large oligomeric species at the top of the gel were not seen when 
IAPP was co-incubated with insulin (Fig. 3.9). From this we surmise that insulin by itself 
does not have the ability to protect β-cells from IAPP toxicity and only inhibits 











Figure 3.10. Cartoon of IAPP and insulin secretion and interactions. The secretory 
vesicles fuse with the plasma membrane releasing their contents into the extracellular 
space. (A) IAPP is costored with crystalline insulin prior to secretion in response to a rise 
in blood glucose within a (B) secretory vesicle. Upon secretion IAPP dissociates from 
crystalline insulin and insulin dissolves to its active form. Secreted (C) insulin and (D) 
IAPP can both stay in their unaggregated forms and fulfill their biological functions as 
peptide hormones. Alternatively, (E) insulin can misfold under certain largely non-
physiological conditions and initiate insulin aggregation into (F) insulin fibrils. IAPP 
forms (G) islet amyloid readily at the high concentrations like those envisioned at the site 
of peptide secretion. Interestingly, (H) islet amyloid would be greatly inhibited by the 
high soluble insulin concentration also experienced at the secretion site. Finally, (I) 
soluble IAPP may bind to the plasma membrane at or near the site of secretion under 
certain conditions: high anionic lipid content of the plasma membrane or the lack of other 
secretory components that would inhibit IAPP membrane binding. 
 
3.4.3 Other Conditions in the Secretory Granule Besides Insulin May Act to Retard its 
Aggregation and Toxicity  
 If insulin is not solely responsible for inhibiting the membrane disruption by 
IAPP, what factors may be responsible for maintaining IAPP in a non-toxic state in the 
secretory granule and immediately after secretion? First, although insulin appears to have 
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little effect on reducing membrane disruption by IAPP in model membranes, it may 
reduce the toxicity of IAPP through other, currently undiscovered mechanisms in the 
complex physiological environment at the protein-lipid interface of the β-cell. It is known 
that the fibrillar form of IAPP can react with copper and zinc to generate reactive oxygen 
species and can also apparently mediate the redox-sensitive JNK apoptotic cascade (93, 
94). In contrast to IAPP membrane disruption, which occurs immediately when IAPP is 
added to cells or membranes, ROS formation by IAPP occurs slowly and is associated 
with IAPP amyloid formation. Insulin may therefore suppress IAPP toxicity by these 
redox-sensitive mechanisms through the suppression of IAPP amyloid formation. 
 Other modulators of IAPP pathology besides insulin should also be taken into 
account when considering the non-toxicity of IAPP in non-diabetic subjects.  Lipid 
binding by IAPP is known to be strongly dependent on the anionic charge of the lipids 
(95, 96). Similarly, we found that the ability of IAPP to permeabilize LUVs is dependent 
on the anionic charge of the LUVs. Previously, 30 mol % anionic lipid content has been 
shown to be the minimum for IAPP binding (1). To avoid working at the breaking point, 
25 mol % anionic content was chosen instead of 30 mol %. We found that at 25%:75% 
POPG/POPC not much permeabilization occurs, yet at 50%:50% POPG/POPC the 
permeabilization increases to ~ 40%. (Fig. 3.3) At 100% POPG concentration the 
permeabilization of LUVs reaches above 80% permeabilization. This confirms the 
importance of anionic lipid content in not only the binding of IAPP, but also the 
disruption and permeabilization of the LUVs. This supports the hypothesis that increased 
anionic lipid content may be a key factor in the development of Type II diabetes arising 
from the increased lipid required for the secretory granules to hypersecrete insulin in 
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response to elevated blood glucose levels in the insulin resistant state. When the anionic 
lipid content is reduced to 25 mol % or 0 mol % in our lipid permeabilization experiment, 
the permeabilization is minimal. The anionic charge ratio of a healthy individual is below 
20 mol % anionic content, well below this critical level for peptide binding and 
permeabilization (1). What would cause a breakdown in the lipid synthesis that leads to 
increased anionic lipid content? Type II diabetes often involves an overall state of 
dyslipidemia as well as a specific increase in anionic phospholipid production in the β-
cells (1, 97). An anionic lipid content above 30 mol % may allow IAPP to bind and 
permeabilize these cells, which would further weaken β-cells and lead them to apoptosis. 
Interestingly, the islets have a limited ability to regenerate β-cell mass. As insulin 
resistance continues to require elevated levels of insulin secretion coordinated with a 
disproportionate increase in anionic lipid synthesis, eventually a significant population of 
β-cells would become overwhelmed and die. The continually stressed islets, after a 
certain tipping point, would be incapable of regenerating the lost β-cell mass faster than 
their destruction. 
 Other peptides exist within the secretory granule that may also play a role in 
sequestering IAPP to prevent self-toxicity of the β-cell. Insulin in the crystalline and 
soluble forms may only play the role of inhibiting fibril growth within the secretory 
granule. Upon secretion, other components may bind to IAPP monomers to inhibit the 
formation of oligomers and to inhibit the peptides from binding to the cellular 
membranes. Prepeptin, C-peptide I and II, and other protein components found within 
secretory granules (98) may be involved in this cooperative inhibition of membrane 
binding and toxicity. Further work needs to be done to determine the components in 
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combination with the lipid charge that prevents IAPP from forming toxic oligomers at the 
site of secretion. Our work shows that insulin does inhibit the formation of IAPP fibrils, 
as previously seen, but does not potentially inhibit the toxic effects of IAPP. Low anionic 
charge in the plasma membrane may be the most important factor preventing IAPP from 
binding and permeabilizing β-cells. 
CHAPTER IV 
 
Cholesterol Protects LUVs Against IAPP Permeabilization 
 
4.1 Introduction 
 Type II diabetes is an amyloid disease much like Alzheimer’s and Parkinson’s 
disease. It involves a peptide hormone, IAPP, which has been implicated in β-cell 
apoptosis, a reduction in β-cell mass, and the progression of insulin resistance to overt 
Type II diabetes. IAPP in the early stages of aggregation correlates well with β-cell 
toxicity, unlike the later forming islet amyloid, which has been suggested to form as an 
end product of aggregation and act as a sink for toxic oligomeric species. Within the 
context of β-cell toxicity, certain requirements are necessary for IAPP to bind and 
permeabilize the plasma membrane. 
The likelihood of developing Type II diabetes increases with age. Previously it 
was termed adult onset diabetes until an increase in childhood cases of Type II diabetes 
emerged in recent years. Two aging associated changes in the plasma membrane are 
discussed in this chapter that could lead to an increase in IAPP binding. These changes 
include (1) an increase in anionic phospholipids, explained previously as possibly 
deriving from a breakdown in lipid regulation, and (2) a decrease in the level of 




4.1.1 An Increase in Anionic Phospholipids 
 The plasma membrane is a bilayer composed of asymmetrically distributed lipids 
and proteins. The lipids and proteins form functional groups or domains within the 
membrane, called lipid rafts. Secreted IAPP, in order to permeabilize the β-cell plasma 
membrane, has to first bind at the protein-lipid interface. A number of characteristics of 
the outside leaflet of the plasma membrane impart an interface that may promote or 
inhibit IAPP binding and subsequent permeabilization. Some of these characteristics are 
membrane surface charge, membrane curvature, phase of the lipid membrane, membrane 
elasticity, chemical nature of the lipids, amount of hydration, lipid acyl chain type 
(saturated or unsaturated), hydrophobic matching of the protein-lipid interface with the 
protein that binds, and the dynamics and conformation of the lipid headgroups (99). The 
anionic phospholipid composition of the plasma membrane has been suggested to be the 
most critical factor for IAPP oligomerization and toxicity (1, 24). 
In healthy individuals the mol % anionic charge of the plasma membrane is 
relatively low—below 20% (1). While it is currently unknown what changes occur to the 
β-cell plasma membrane in the diabetic state, it has been suggested that elevated levels of 
anionic lipids are present in the Type II diabetic state (1). Dyslipidemia and the 
hypersecretion of IAPP and insulin from secretory granules may lead to a breakdown in 
the cell machinery involved in lipid synthesis and turnover. To secrete the high volumes 
of IAPP and insulin, vast amounts of secretory granule lipids have to be synthesized and 
recycled. A breakdown in lipid regulation in Type II diabetes has been suggested to lead 
to an increase in phosphatidic acid (PA), which is negatively charged and would lead to 
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an increase in the overall negative charge of the membrane. An increase to about 30 mol 
% anionic lipid content is known to be needed for peptide binding in vitro (1, 14). 
Zhu et al. showed that when the overall membrane surface charge is opposite to 
the overall charge of the amyloid peptide, the electrostatic charge attracts the peptides 
creating a local amyloid peptide concentration roughly two orders of magnitude greater 
than that observed in solution (100, 101). The electrostatic charge interaction occurs 
when positively charged IAPP is incubated with lipids that impart an anionic charge to 
the membrane. Using lipids from Type II diabetic pancreatic tissue, Knight and Miranker 
found that lipids from diabetic tissue accelerate aggregation more than ten-fold over the 
absence of lipid (1). Type II diabetics’ pancreatic lipid composition may be highly prone 
to IAPP binding and permeabilization. 
 
4.1.2 A Decrease in the Level of Membrane Incorporated Cholesterol 
 Cholesterol (figure 4.1) is an unusual lipid molecule made of four hydrocarbon 
rings, making it extremely hydrophobic, and it has a very small hydroxyl moiety as its 
head group (102). The hydrophobic region of cholesterol preferentially associates with 
the hydrophobic tail regions of the lipid molecule of the plasma membrane. The hydroxyl 
group of cholesterol associates with the phospholipid head groups of the lipids. Because 
of the small size of cholesterol and its lack of a large head group, it fits within the 
interstitial spaces between neighboring lipid tails and functions to restrict and order the 
acyl chains of neighboring lipids, thickening the bilayer in the process (102). The ring 
system in effect rigidifies the membrane making it more impervious to permeabilization 
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Figure 4.1. Cholesterol structure. Cholesterol is amphiphathic with a hydrophobic ring 
structure and a small hydroxyl head group 
 
As an individual ages, membrane localized cholesterol is known to decrease in 
some tissues like the brain, while circulating levels typically rise. Thus, aging-associated 
changes to the plasma membrane may play a role in the development of Type II diabetes. 
Overall, no significant changes in total incorporated cholesterol in the pancreas have been 
observed with aging (104), although this drop in cholesterol could still occur in a subset 
of pancreatic cells like the β-cells. Several conditions could result in a decrease in 
incorporated cholesterol within cellular membranes. One possibility is that the β-cells 
hypersecrete insulin in the insulin-resistant state, creating large quantities of secretory 
granule lipids. The secretory granule lipids in this stressed state may have a 
disproportionately low cholesterol content. Other pancreatic cells do not have these 
secretory requirements, so an unchanged total cholesterol composition of the pancreas 
may not accurately represent localized changes in cholesterol content. Decreases in 
cholesterol have been implicated and studied with amyloid-β and other amyloid peptides, 
but have hardly been explored with IAPP. 
The plasma membrane is a highly ordered membrane and has a high concentration 
of incorporated cholesterol in comparison to organelles within the cell. Cholesterol is the 
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main sterol found in mammals with the majority (90%) incorporated into the plasma 
membrane and the rest in other organelle membranes and the circulation (105). In 
comparison with the plasma membrane, the endoplasmic reticulum (ER) where 
cholesterol is synthesized is very low in incorporated cholesterol and high in unsaturated 
lipids (102). The majority of the cholesterol in the cell is synthesized and transported 
from the ER to the other organelles of the cell, most notably the plasma membrane (105). 
The secondary or minor sources of cholesterol are from the hydrolysis of cholesterol 
esters in the lysosomes and late endosomes or from the endocytosis of lipoproteins that 
contain cholesterol, e.g. low-density lipoprotein (LDL) (106). 
 Despite the negative publicity, cholesterol is actually required for cell viability 
and proliferation (105). The plasma membrane typically has a cholesterol concentration 
of 30 mol % (107). Cholesterol does not uniformly distribute itself within the plasma 
membrane, but clusters in transitory lipid rafts with a diameter <10 nm (108). These lipid 
rafts with cholesterol form patches of lipids that are in the liquid ordered phase and 
surrounded by a liquid disordered phase with lower cholesterol content and more 
unsaturated lipids (105). Much research on lipid rafts or microdomains has led to the 
understanding that they are essential for protein recognition and signal transduction 
pathways (108). It is not known if IAPP preferentially binds to the lipid rafts or to non-
raft containing regions.  
IAPP in itself is sensitive to the membrane environment, especially the lipid 
charge and the presence of cholesterol incorporated into the membrane. Cholesterol has a 
significant impact on reducing permeabilization by IAPP. Previously, Pamela Wong in 
our laboratory used laurdan to characterize the rigidity of the membrane upon the 
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incorporation of cholesterol into POPG/POPC membranes (109). Laurdan is a fluorescent 
molecule with a long hydrophobic tail that intercalates into the membrane situating its 
naphthalene ring structure in the region of the lipid glycerol backbone near the polar 
headgroups and hydrophilic protein-lipid interface. The naphthalene ring of laurdan is 
sensitive to polarity and has two emission peaks, one at 480 and another at 435 nm. 
Depending on the fluidity of the membrane environment, the emission spectrum changes 
from red shifted in a fluid membrane to blue shifted in a rigid cholesterol-containing 
membrane environment. When the membrane is more fluid, water molecules can interact 
with the fluorescent naphthalene ring. Pamela Wong showed that the membrane becomes 
more rigid with the incorporation of cholesterol. Less space is available between the 
phospholipid head groups for water molecules to interact with the naphthalene ring, 
which changes the polar environment of the naphthalene ring and emission peaks. Pamela 
Wong found that 25 mol % cholesterol was similar in packing density to a gel phase 
membrane, showing that cholesterol rigidifies the membrane and could greatly reduce the 
ability of amyloid peptides to insert into the membrane (109). 
The status of cholesterol in terms of amyloid diseases is unclear, as the research 
literature presents various reports ranging from findings that cholesterol is protective 
against membrane permeabilization to findings that cholesterol is detrimental to 
membrane stability. Cholesterol has been identified as a possible risk factor for some 
amyloid diseases like Alzheimer’s disease and Type II diabetes because it is often found 
in plaques and fibrils, and high serum levels have been reported to be associated with the 
disease states (103, 110). Yet in an interesting scientific finding, cholesterol-lowering 
statins have been found to increase amyloid production in humans and rodents (111, 
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112). Several studies show the possible benefits of cholesterol, especially when it is 
incorporated into the membrane, rather than the circulation (109, 113, 114). If cholesterol 
is protective against amyloid peptide membrane permeabilization, then statins and other 
cholesterol lower drugs may increase cell death and accelerate the progression of Type II 
diabetes. The exact role cholesterol plays at the interface of the membrane and IAPP at 
the site of secretion is currently in question. The presence of cholesterol in the membrane 
should make it more difficult for an amyloid peptide to insert between the headgroups 
and acyl tails to permeabilize the membrane. It takes several times more work for an 
amyloid peptide to insert into a cholesterol containing membrane to create a vacancy 
between the lipids than it does with a membrane without cholesterol (108, 115, 116). The 
studies presented here show that membrane incorporated cholesterol inhibits IAPP 
permeabilization of model lipid membranes. 
 
4.2 Material and Methods 
 
4.2.1 IAPP and Insulin Preparation 
Human IAPP was purchased from Anaspec Inc., recombinant human insulin 
expressed in yeast was purchased from Sigma-Aldrich. The IAPP peptide used in this 
study was amidated at the C-terminus like the natural peptide. Preformed aggregates in 
both peptides were solubilized by first dissolving the peptide in a 75% acetonitrile/water 
solution at a concentration of 1 mg/ml. The peptides were then lyophilized and the 
lyophilized powder was redissolved in hexafluoroisopropanol (HFIP) at a concentration 
of 2-4 mg/ml. HFIP was removed by lyophillization overnight at high vacuum (72). The 
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peptide was first dissolved in pure water to a concentration of 25 µM in siliconized 
eppendorf tubes and then diluted with 2x buffer to create the final working solution (final 
buffer composition: 10 mM Sodium Phosphate, pH 7.4 100 mM NaCl) (73). 
 
4.2.2 Liposome Preparation 
1-Palmitoyl-2-Oleoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)] (POPG) and 1-
Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine (POPC) dissolved in chloroform were 
purchased from Avanti Inc. (Alabaster, AL). To make liposomes, chloroform lipid stocks 
were dried with a stream of nitrogen and then placed under vacuum overnight to remove 
residual solvent. The lipid films were then rehydrated for 1-2 hours with 10 mM NaPi, 
buffer at pH 7.4 buffer containing 100 mM NaCl. The rehydrated lipids were vortexed 
and then subjected to 8 freeze-thaw cycles. The resulting multilamellar vesicles were 
extruded 21 times through two 100 nm polycarbonate Nucleopore membrane filters 
(Whatman) to create unilamellar vesicles. 
For liposomes with encapsulated dye, the vesicles were created as above except 
the buffer also contained 50 mM 5(6)-carboxyfluorescein. Free dye was separated from 
the vesicles with encapsulated dye by running the sample through a 10 mL Sephadex G-
50 gel filtration column (Sigma-Aldrich, St. Louis, MO). Lipid concentrations were 
determined using the Stewart method (32). 
 
4.2.3 Liposome Preparation with Cholesterol 
 Cholesterol (Sigma-Aldrich, St Louis, MO) was dissolved in chloroform, mixed 
with POPG, POPC, or POPG/PC in mol % ratios used in the experiments. The lipid stock 
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mixtures were aliquoted into test tubes, dried with a stream of nitrogen, and then placed 
under vacuum overnight to remove residual solvent. Rehydration and extrusion were 
conducted as described for general liposome preparation. 
 
4.2.4 Dye Leakage 
IAPP or IAPP/insulin was solublilized to a 25 µM concentration and then diluted 
to 1 µM upon addition to a 200 µM mixture of LUVs (195 µM empty POPG vesicles, 5 
µM dye-encapsulated POPG vesicles). The fluorescence of leaked dye was recorded for 
the LUV mixture prior to the addition of the peptide and subtracted from the 
measurements of the sample. The dye leakage was monitored for an hour or more over 
the course of the experiment. At the end of the incubation, the total fluorescence was 
determined and normalized by adding Triton-X detergent to 0.2% v/v to permeabilize any 





4.3.1 Cholesterol Has an Inhibitory Effect on IAPP Permeabilization of POPG/POPC 
Membranes 
 Cholesterol is a predominant cellular component and has been suggested to play a 
role in amyloid diseases and toxicity, although there have been disagreeing statements 
about the effects of cholesterol. Using POPG/POPC LUVs with carboxyfluorescein 
encapsulated inside, varying levels of incorporated cholesterol were monitored for their 
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effects on the ability of IAPP to permeabilize these liposomes as measured by released 
dye. At 25 mol % cholesterol a slight reduction in IAPP permeabilization was observed 
and at 50 mol % cholesterol permeabilization by IAPP was almost completely blocked 




Figure 4.2. Cholesterol inhibits IAPP from permeabilizing POPG/POPC LUVs.  
IAPP was added to POPG/POPC dye leakage lipids with cholesterol and monitored over 
a 60 min timecourse. The peptides were added at time zero and the fluorescence was 
monitored for the duration of the experiment. The cholesterol containing samples were 
composed of mol % cholesterol and mol % lipid. 
 
4.3.2 Cholesterol Has an Inhibitory Effect on IAPP Permeabilization of POPG 
Membranes 
To better observe the permeabilization of LUVs, POPG LUVs were used in a 
similar manner to see if cholesterol was capable of inhibiting IAPP permeabilization, 
even with 100% anionic POPG component. Cholesterol reduced the IAPP induced 
permeabilization from above 70% to 10% leakage with 50 mol % cholesterol 
incorporated into the POPG LUVs (figure 4.3). Cholesterol (40 mol %) was nearly as 
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effective as 50 mol % with roughly only a 15% reduction in dye leakage. The effect of 
cholesterol was strong enough to inhibit IAPP permeabilization, although it did not 
prevent permeabilization completely. 
 
Figure 4.3. Cholesterol inhibits IAPP from permeabilizing POPG LUVs. The same 
basic experiment as figure 4.1 was repeated with POPG LUVs. IAPP was added to POPG 
dye leakage liposomes one time and monitored for 60 min for dye leakage in the presence 
of cholesterol. The experiment used 1 μM IAPP and 200 μM POPG LUVs (5 μM POPG 
LUVs with encapsulated dye and 195 μM unlabeled POPG LUVs). The cholesterol 
containing samples were composed of mol % cholesterol and mol % lipid.  
 
IAPP was incubated with equimolar insulin to more closely approximate the 
conditions at the site of secretion, where soluble insulin and IAPP are co-secreted. Even 
with the presence of insulin, IAPP permeabilization of LUVs was nearly identical to 
IAPP alone, showing that insulin and cholesterol do not inhibit IAPP binding to anionic 
lipid membranes (figure 4.4). 
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Figure 4.4. Cholesterol inhibits IAPP/insulin from permeabilizing POPG LUVs. 1 
μM IAPP/1 μM insulin. The cholesterol containing samples were composed of mol % 
ratios. 
 
Insulin was added to POPG dye labeled LUVs to see if cholesterol altered the 
affinity of insulin for the membrane. This shows that cholesterol does not have any 





Figure 4.5. Insulin has little effect on POPG LUVs. 1 μM IAPP/1 μM insulin. in mol 
% ratios. The effect of sphingomyelin on dye leakage with 1 μM insulin. 
Cholesterol:POPG (C:P) in mol % ratios. The cholesterol containing samples were 




4.4.1 Membrane Charge Is a Key Determinant of IAPP Binding 
The IAPP identified in plaques and fibrils in diabetic patients has not been found 
to be altered from the wild-type amino acid sequence, leading to the idea that changes in 
the plasma membrane and the surrounding environment increase or decrease the potential 
toxicity of IAPP (1). The most abundant protein in the secretory granule is insulin, which 
has been suggested to inhibit IAPP toxicity when insulin is in its crystalline form. Shown 
previously in Chapter III, soluble insulin does not inhibit IAPP from forming oligomers, 
binding to lipid membranes, or permeabilizing them. Other secretory granule components 
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or membrane components in the outer leaflet of the plasma membrane, like membrane 
charge, may play a role in inhibiting IAPP toxicity in the non-diabetic state. 
Large unilamellar vesicles (LUVs) containing anionic lipids have been known for 
some time to accelerate the aggregation of several amyloid peptides, including IAPP and 
amyloid-β. IAPP rapidly binds and permeabilizes these LUVs, while amyloid-β binding 
and permeabilization is relatively low early in the incubation. One key difference exists 
between these two peptides. Amyloid-β is natively negatively charged until it undergoes 
a conformational change to expose its positively charged residues. IAPP is natively 
positively charged and is immediately capable of binding to anionic LUVs. The charged 
plasma membrane acts as a local attractant to IAPP peptides, congregating them in a 
localized area that creates a high concentration capable of forming the toxic oligomeric 
species and in later stages or at higher concentration forms IAPP fibrils extending out 
from the membrane (see Figure 3.4A). This explains how membrane charge can act as an 
accelerant for IAPP aggregation by creating localized pockets of high peptide 
concentration. This high local peptide concentration has been proposed to overcome the 
nucleation energy barrier, skipping the lag phase or nucleation phase of amyloid 
formation (see IAPP in Figure 3.1A) (101, 117, 118). 
In the diabetic state, a breakdown in lipid biosynthesis may lead to an imbalance 
in zwitterionic and anionic lipids with a greater percentage of anionic lipid content. In 
addition, when phospholipases cleave the choline head group of PC, it results in the 
negatively charged phosphatidic acid (119). If there is breakdown in lipid turnover, 
anionic PA would temporarily accumulate again, leading to an increase in anionic charge 
and affinity for IAPP binding (1). 
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4.4.2 Is Cholesterol Protective Against Permeabilization of LUVs? 
Why would cholesterol inhibit IAPP permeabilization? Cholesterol has a rigid 
hydrocarbon ring structure that intercalates between the lipid acyl chains. The hydroxyl 
head group of cholesterol binds to the phospholipid head group. Cholesterol fills the 
interstitial space, reducing the ability of the lipid tails to move in response to peptide 
binding or insertion. Cholesterol adds a steric constraint on the lipid membrane that 
inhibits IAPP permeabilization. Whether the interaction of cholesterol with the polar lipid 
headgroup exerts a decrease in the electrostatic charge of the lipid surface that would 
reduce the affinity of IAPP is unknown, as this work only sought to address the 
permeabilization at varying levels of cholesterol. 
In the absence of cholesterol, IAPP readily binds to membranes that contain a 
minimum anionic lipid content of 30 mol % (figure 4.6A). As the cholesterol content is 
increased to 25 mol % the ability of IAPP to permeabilize the membrane decreases 
(figure 4.6B). At high concentrations of incorporated cholesterol (50 mol %) IAPP is 




Figure 4.6 Cartoon of membranes with incorporated cholesterol inhibiting IAPP 
permeabilization of LUVs. The cholesterol (orange rectangles) stabilizes the membrane, 
preventing IAPP (shown in green) from permeabilizing the membrane. (A) A toroidal 
pore caused by IAPP permeabilization of the membrane. The toroidal mechanism is one 
of several pore types hypothesized as the mechanism of IAPP permeabilization of the β-
cell membrane. (B) Incorporating a small amount of cholesterol  into the membrane 
reduces membrane permeabilization. (C) Higher concentrations of cholesterol 
incorporated into the membrane completely exclude IAPP from permeabilizing the 
membrane similar to what would be expected with gel phase membranes. 
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Cholesterol in the membrane is a necessity for cellular function, liquid-order 
phase, and lipid rafts. Cholesterol has been termed the most important regulator of lipid 
organization, and complex controls are involved to maintain correct levels of 
incorporated cholesterol (106). In light of this, the notion that cholesterol is always bad 
and that it needs to be reduced in individuals is potentially inappropriate. Incorporated 
cholesterol decreases with age, changing liquid-ordered to liquid-disordered regions. 
Care needs to be applied to separate incorporated cholesterol levels from circulating 
cholesterol. The effects of statin drugs may also pose a particular problem if they, in the 
process of reducing circulating cholesterol, reduce the ability of cells to synthesize and 
incorporate cholesterol into their plasma membranes. A decrease in incorporated 
cholesterol could foster the progression of Type II diabetes as well as other amyloid 
diseases. Further work needs to be done to elucidate the role that cholesterol and other 
cellular components play in protecting cells from toxic amyloid peptides. Regions high in 
anionic charge and low in cholesterol content may be the at risk regions of the β-cell 
plasma membrane where IAPP readily binds and permeabilizes the cell if the anionic 






 This body of work has focused on identifying the IAPP peptide region responsible 
for membrane binding, elucidating the interaction of insulin with IAPP, and the role that 
cholesterol plays in regulating membrane fluidity and in protecting from IAPP 
permeabilization of model lipid membranes. This chapter seeks to summarize the 
conclusions and findings of the previous chapters, Chapters I through IV. The 
Significance and Future Studies section focuses on future directions and experiments 
involving IAPP oligomerization and toxicity. 
 
5.2 Thesis Summary 
 
5.2.1 Chapter I. 
Typically eukaryotic cells are largely composed of zwitterionic (effectively 
neutral) lipids with an anionic component of 20 mol % or less. Accordingly, many of the 
antimicrobial peptides produced by eukaryotes bind specifically to anionic membranes 
that would be found on microbial membranes (13). This is also the case with IAPP. IAPP 
is positively charged and binds readily to negatively charged surfaces similarly to 
antimicrobial peptides. IAPP is also known to interact readily with anionic lipids, such as 
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the specifically identified lipids, glycerol and serine-containing phospholipids (120). 
Lys1, Arg11, and His18 are all located within the N-terminal membrane binding region of 
IAPP and are positively charged at neutral pH, creating strong electrostatic interactions 
with negatively charged substances. Insulin is also negatively charged at pH 7.4, leading 
to its electrostatic interactions with IAPP. IAPP preferentially binds anionic lipids over 
insulin when both are present. These charge interactions appear to play a large role in the 
ability of IAPP to bind and subsequently permeabilize LUV membranes. Conditions that 
favor an anionic lipid membrane would allow IAPP binding if the anionic charge was 30 
mol % or greater unless cooperative inhibition from secreted secretory granules could 
temporarily bind and inhibit IAPP interaction with anionic membranes. 
 
5.2.2 Chapter II. Amyloid Fibril Formation and Membrane Disruption are Separate 
Processes Localized in Two Distinct Regions of IAPP, the Type-2-Diabetes-Related 
Peptide 
 In Chapter II the fragment IAPP(1-19) was compared with the full-length amidated 
IAPP(1-37) for their ability to permeabilize LUVs and form amyloid. This study made a 
key finding by separating the membrane binding region of IAPP located in the (1-19) 
region from the amyloid forming regions of the peptide (20-29) and (30-37). This showed 
for the first time that amyloid formation is not a necessary step for permeabilization. 
IAPP(1-37) had a reduced ability to permeabilize LUVs when the concentration was above 
the critical concentration for aggregation. This supports the idea that amyloid formation 
may be protective, acting as a sink for toxic peptides, and supports the oligomeric 
hypothesis of toxicity. IAPP(1-19) did not form amyloid as measured by circular dichroism 
 74
or thioflavin T assay. No amyloid formation occurred even in the presence of anionic 
LUVs, unlike the full-length peptide that underwent a rapid conformational change from 
α-helical to β-sheet conformation with the addition of anionic LUVs. The C-terminus 
drives amyloid formation, whereas the N-terminus is responsible for membrane binding 
and toxicity. In addition the disulfide bond blocks the ability of the N-terminal region to 
form amyloid. 
 
5.2.3 Chapter III. Insulin Stabilizes the Membrane Permeabilizing Species of Islet 
Amyloid Polypeptide 
 The interaction between IAPP and insulin has been suggested to be protective 
because it is well known that insulin inhibits IAPP fibrillization. Unfortunately insulin 
does not also inhibit IAPP oligomerization and IAPP induced permeabilization of LUVs.  
 Insulin appears to bind and inhibit fibril formation and does not have much if any 
effect on IAPP in the early stages of oligomerization. In accordance with this, dye 
leakage experiments show that insulin, by inhibiting the fibrillization, prolongs the 
oligomeric state of IAPP. This also prolongs the time period that IAPP can readily bind 
and permeabilize lipid membranes. Insulin only inhibits amyloid formation, not small 
oligomers, and most surprisingly IAPP rapidly permeabilizes membranes even in the 
presence of insulin. 
 Interestingly IAPP may bind directly to the membrane as a monomer based on the 
electrostatic interaction between the membrane and peptide, not requiring a structural 
change and oligomerization prior to membrane binding. Oligomerization of IAPP may 
 75
occur on the membrane surface, which would explain the immediate permeabilization 
after the addition of IAPP to LUVs. 
 Oligomerization appears to be independent of the effects of insulin as observed in 
the crosslinking experiment. The same sized oligomeric species were present in both 
samples, showing that insulin does not readily bind the early states of IAPP aggregation, 
only later fibrillar forms. 
 Membrane charge appears to be the main determinant of IAPP binding in our 
experiments. Whether insulin is present or not, a minimum anionic charge of 30 mol % is 
necessary for permeabilization. At 25 mol % anionic lipid content, not much 
permeabilization occurs. 
 
5.2.4 Chapter VI. Cholesterol Protects LUVs Against IAPP Permeabilization 
The role of cholesterol in amyloid diseases is unclear at the present time, but this 
research shows support for cholesterol as playing a protective role inhibiting IAPP 
permeabilization of model lipid membranes. Cholesterol at 25 mol % reduced IAPP 
binding by approximately 15%. At 50 mol % the rigidity of the membrane becomes 
similar in fluidity to a gel phase membrane based on the stabilization of cholesterol. 
Accordingly, cholesterol at 50 mol % lipid concentration was highly effective at 
inhibiting IAPP permeabilization. 
 
5.3 Significance and Future Studies 
 The significance of this work is that it shows that amyloid formation and amyloid 
peptide toxicity are separate parts of the peptide. This work supports the oligomeric 
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hypothesis, that smaller oligomeric species are responsible for β-cell death in Type II 
diabetes rather than the formation of islet amyloid and the growth of the fibrils. This 
research supports and extends Knight and Miranker’s recent work involving IAPP 
binding and anionic charge (1), but shows that not only binding is occurring but 
permeabilization is occurring as well. Miranker also showed that crystalline insulin is 
protective against IAPP oligomerization and toxicity within the secretory granules (51). 
In addition, the greatest risk of IAPP toxicity may be at the site of secretion from the 
secretory granules when insulin becomes soluble, as we clearly show that insulin is only 
effective at inhibiting amyloid fibril formation and not the early oligomeric species or the 
ability of these species to permeabilize the membrane. In addition, we showed that 
incorporated cholesterol is protective against IAPP permeabilization. 
It would be interesting to look at the interaction of IAPP with other secretory 
granule components, like Prepeptin, C-peptide I, and C-peptide II, and then observe the 
effect IAPP has on membrane permeabilization when they are added in conjunction with 
these other components. Further work needs to be done to determine the components and 
lipid charge that prevent IAPP from forming toxic oligomers within the secretory 
granules.  
 Further investigation needs to be conducted to elucidate the exact changes that 
occur in the plasma membrane in the diabetic state, both changes in the lipid components 
and the anionic charge of the membrane. Greater understanding of the conditions and 
mechanism of IAPP binding and permeabilization could allow the development of better 
prevention strategies and treatments to prevent further β-cell loss in the insulin resistant 
and diabetic states. 
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 In all of these experiments we observed membrane permeabilization of our model 
lipid membranes. It would be interesting to observe toxicity in cell culture experiments 
with MIN6 cells (immortalized insulin secreting murine pancreatic cell line). However, 
MIN6 cells express insulin receptors and are sensitive to changes in insulin 
concentrations. Adjusting the insulin level could lead to apoptosis in MIN6 and other 
insulin sensitive cell lines. Insulin insensitive cells would need to be used to conduct 
experiments that use a combination of insulin and IAPP. A possible candidate for these 
experiments would be Madin-Darby canine kidney (MDCK) cells, which lack insulin 
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